Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 31 2025
0mins
Source: Globenewswire
PALI-2108 Development: Palisade Bio has received a Notice of Allowance for a patent in China covering PALI-2108, a PDE4 inhibitor aimed at treating fibrostenotic Crohn’s disease and ulcerative colitis, with a potential market revenue nearing $1 billion by 2030.
Clinical Trials and Future Prospects: The company is currently conducting a Phase 1b/2a clinical trial for PALI-2108 and emphasizes the importance of strengthening its intellectual property portfolio to support long-term value and upcoming clinical milestones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
